Eyepoint Pharma (EYPT)
NASDAQ:EYPT
Want to see EYPT full AI Analyst Report?
EYPT Stock Chart & Stats
$14.93
$0.01(0.11%)
At close: 4:00 PM EST
$14.93
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$7.94 - $19.11
Previous CloseN/A
Volume354.62K
Average Volume (3M)1.02M
Market Cap
$1.14B
Enterprise Value$1.05B
Total Cash (Recent Filing)$222.54M
Total Debt (Recent Filing)$20.23M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Aug 05, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding83,841,300
10 Day Avg. Volume1,166,734
30 Day Avg. Volume1,019,531
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.37
Price to Sales (P/S)42.66
P/FCF Ratio-5.50
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue137.23
Enterprise Value/Gross Profit179.37
Enterprise Value/Ebitda-4.02
Forecast
1Y Price Target
$37.57Price Target Upside151.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.54
Revenue Forecast (FY)$1.73M
Bulls Say, Bears Say
Bulls Say
Phase III Wet AMD ProgressFully enrolled pivotal LUGANO/LUCIA trials with mid-2026 topline timing are durable value drivers: successful readouts could enable regulatory filings and first-to-market positioning for a six-month sustained-release therapy, materially altering commercial prospects in a large retinal market.
Differentiated Multi-mechanism MOAA multi-mechanism TKI that targets VEGF, PDGF and IL-6 pathways could offer clinical differentiation versus pure anti-VEGF agents. If durable efficacy and safety hold in late‑stage trials, the MOA supports sustainable competitive advantage and broader clinical utility across retinal indications.
Manufacturing & Commercial ReadinessAn on‑site cGMP facility plus added commercial/regulatory hires reduce execution risk for CMC, NDA submission and launch logistics. Durable manufacturing capability and ambient storage/standard administration lower commercialization friction versus peers reliant on external supply.
Bears Say
Severe Revenue ContractionA dramatic decline in revenue erodes operating leverage and scale, leaving fixed R&D and commercial costs unsupported. Over months this undermines internal funding capacity and increases dependence on external financing before any product commercialization can restore sustainable top-line growth.
High Cash Burn And Negative Cash FlowPersistent negative operating and free cash flow reflect real cash depletion driven by trial and scale-up spend. Even with runway into Q4 2027, ongoing burn raises financing and dilution risk if regulatory or commercial timelines slip, pressuring long‑term capital structure and strategic optionality.
Rising Operating LossesEscalating operating expenses and widening net losses show the cost base is increasing ahead of revenue recovery. This misalignment can prolong negative returns, strain equity, and force reprioritization of programs if late‑stage results or regulatory reviews delay commercial revenue.
EyePoint Pharmaceuticals News
EYPT FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was $7.94 and its highest was $19.11 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is $1.14B.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Aug 05, 2026 which is in 46 days.
How were Eyepoint Pharma’s earnings last quarter?
Eyepoint Pharma released its earnings results on May 06, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.805 by -$0.185.
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.94.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 83,841,300 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Eyepoint Pharma reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.805. Following the earnings report the stock price went down -2.909%.
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in EYPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.57 (151.65% Upside)
$37.57 (151.65% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $36.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.24%
12-Months-Change
Fundamentals
Return on Equity
-110.54%
Trailing 12-Months
Asset Growth
-20.51%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
EYPT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed robust clinical and operational momentum: imminent Phase III wet AMD readouts, strong DME enrollment, favorable Phase II data and a differentiated MOA, supported by manufacturing and commercial preparations. Offsetting this are steep year-over-year revenue decline (driven by prior deferred revenue recognition), rising operating expenses, a larger quarterly net loss and a notable quarter-over-quarter cash reduction. Management projects cash runway into Q4 2027, and masked safety data and DSMC recommendations to date are favorable. Overall, the clinical and strategic positives tied to near-term pivotal catalysts moderately outweigh the financial headwinds.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$37.57
▲(151.65% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
10.76% Insiders
19.58% Mutual Funds
50.08% Other Institutional Investors
8.05% Public Companies and
Individual Investors